Barry J. Simon, M.D., is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He previously served on Viracta’s board from July 2017 to November 2020 and has been serving as Director and CCAO of Immunity Bio, Inc. since March 2021. Prior to this, he served as President and Chief Administrative Officer of Nantkwest, Inc. since 2015 and as its President and CEO since 2007. Dr. Simon also serves on the boards of Cue BioPharma and Brink Biologics Inc. He has broad experience in public and private companies, having led private and public equity offerings, product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, IND and BLA regulatory filings, human-enabling programs, and manufacturing, quality control and life cycle management projects. Previously, he held Vice President, senior level and advisory positions at F. Hoffmann-La Roche, Roche Labs, Connetics Corporation, Immunomedics, Immusol, HealthPro BioVentures, LLC, and NorthSound Capital, LLC.
In his prior roles, Dr. Simon worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on product launches including Xeloda®, Pegasys®, Fortovase®, Tamiflu®, Camptobell®, Boniva®, Fuzeon®, Valcyt®, and Accutane®. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He received his M.D. from the SUNY Downstate Health Sciences Center in New York and trained clinically in infectious diseases, anesthesiology, and internal medicine at Albert Einstein College of Medicine, The Mount Sinai Medical Center and New York University, respectively.
What is Barry J. Simon's net worth?
The estimated net worth of Barry J. Simon is at least $18.05 million as of May 21st, 2021. Dr. Simon owns 3,212,517 shares of ImmunityBio stock worth more than $18,054,346 as of April 23rd. This net worth evaluation does not reflect any other assets that Dr. Simon may own. Learn More about Barry J. Simon's net worth.
How old is Barry J. Simon?
Dr. Simon is currently 59 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Hans Georg Klingemann M.D., Ph.D., Chief Science Officer of Cellular, who is 74 years old. Learn More on Barry J. Simon's age.
How do I contact Barry J. Simon?
Has Barry J. Simon been buying or selling shares of ImmunityBio?
Barry J. Simon has not been actively trading shares of ImmunityBio during the last ninety days. Most recently, Barry J. Simon sold 21,223 shares of the business's stock in a transaction on Monday, May 24th. The shares were sold at an average price of $16.02, for a transaction totalling $339,992.46. Following the completion of the sale, the director now directly owns 3,212,517 shares of the company's stock, valued at $51,464,522.34. Learn More on Barry J. Simon's trading history.
Who are ImmunityBio's active insiders?
Are insiders buying or selling shares of ImmunityBio?
In the last year, ImmunityBio insiders bought shares 2 times. They purchased a total of 96,915 shares worth more than $268,516.25. The most recent insider tranaction occured on June, 5th when Director Michael D Blaszyk bought 71,915 shares worth more than $197,766.25. Insiders at ImmunityBio own 83.4% of the company.
Learn More about insider trades at ImmunityBio. Information on this page was last updated on 6/5/2023.
